FDA Gives Green Signal To Sanofi-Aventis SA's Cancer Drug Taxotere
French drug maker Sanofi-Aventis SA announced on Thursday that the US Food and Drug Administration has approved its cancer drug Taxotere to treat patients with stomach cancer.// This approval means that Taxotere can be used in combination with chemotherapy drugs cisplatin and 5-fluorouracil to treat stomach cancers that have not been treated with chemotherapy. Taxotere is also approved...Sanofi-Aventis sets the ball rolling for trials of H7N1 bird flu vaccine
Sanofi-Aventis SA has announced that it has begun the clinical trials of a purported vaccine for the H7N1 bird flu strain, a different but equally ferocious strain that// could spark off a potential pandemic. 60 adults at the Haukeland University Hospital in Bergen, Norway will be subjects of the clinical trials to be conducted by Sanofi Pasteur. The H5N1 strain of bird flu virus had...Diabetes II May Be Controlled By Sanofi's New Obesity Pill
Sanofi-Aventis' Accomplia (rimonabant), a new drug for treatment of obesity, has been found to control blood sugar and reduce risk of cardiac problems// in people with diabetes type 2. The research was done on 1,047 overweight or obese patients with type 2 diabetes in Europe and south and North America. Some of them were given 5 or 20 mg/day of rimonabant, while the others were treat...Sanofi-Aventis Allows Thais To Make Plavix
The generic version of Plavix, the heart disease medicine of Sanofi-Aventis will be made indigenously in Thailand. This was announced by the pharma company on Tuesday.// As per the offer made by Sanofa-Aventis, the health ministry has approved plans to buy or make imitated version of the drug. The statement released by the drug firm states that indigenous making of the heart drug will b...Sanofi Withdraws Anti-obesity Drug in US
French pharmaceutical group Sanofi-Aventis said Friday it had withdrawn an application for regulatory approval for its anti-obesity drug Acomplia in the United States. A panel of experts from the US Food and Drug Administration concluded earlier this month that the dieting treatment, referred to as rimonabant by the company, was unsafe and should not be sold in the United States. <...Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research
New data on Eloxatin(R), Taxotere(R) and on three investigationalagents (VEGF Trap, S-1 and TroVax(R)) will be presented at the 43rdannual ASCO meeting BRIDGEWATER, N.J., May 29, 2007 /PRNewswire-FirstCall/ --Sanofi-aventis announced today that a total of 375 abstractsindicative of its oncology commitment have been accepted for the43rd Annual Meeting of the American Society of Clinical On...